| | 1110813-31-4 Basic information More.. |
| Product Name: | Dacomitinib (PF299804) | | Synonyms: | PF-00299804-03;PF-00299804;DacoMitinib (PF-00299804);DacoMitinib,PF299804;DacoMitinib (PF299804,PF-00299804);PF299804;DACOMITINIB;DacoMitinib (PF299804, PF299);(E)-N-(4-((3-chloro-4-fluorophenyl)aMino)-7-Methoxyquizolin-6-yl)-4-(piperidin-1-yl)but-2-eMide | | CAS: | 1110813-31-4 | | MF: | C24H25ClFN5O2 | | MW: | 469.94 | | EINECS: | 000-000-0 | | Mol File: | 1110813-31-4.mol |  |
Use
Dacomitibib (Dacomitinib, PF299804) is an effective and irreversible pan-ErbB inhibitor that is most effective in EGFR, with an IC50 of 6 nM. It is also highly effective in NSCLCs that carries EGFR or ERBB2 mutants (against Gefitinib) and EGFR T790M mutant. Phase 2.
Dacomitinib is taken orally once-daily. It is an irreversible inhibitor of HER-1 (EGFR), HER-2 and HER-4 tyrosine kinases. Dacomitinib targets multiple receptors of the HER pathway, whereas currently marketed HER-1 (EGFR) inhibitors for non-small cell lung cancer (NSCLC) target only one receptor in this pathway,developed by Pfizer.
- Dacomitinib
-
- US $0.00 / g
- 2024-03-12
- CAS:1110813-31-4
- Min. Order: 1g
- Purity: 98% HPLC
- Supply Ability: 1kg
- Dacomitinib (PF299804)
-
- US $60.00-600.00 / kg
- 2024-01-02
- CAS:1110813-31-4
- Min. Order: 10kg
- Purity: 0.99
- Supply Ability: 20tons
- Dacomitinib
-
- US $0.00-0.00 / kg
- 2023-12-23
- CAS:1110813-31-4
- Min. Order: 1kg
- Purity: 99%，single impurity＜0.1
- Supply Ability: 1 ton
|
|
1110813-31-4
Recommend Suppliers |
|